Comparison of the ocular beta-blockers

Annals of Pharmacotherapy

Volumn 30, Issue 1, 1996, Pages 43-54

  Sorensen, Suellyn J ^a   Abel, Steven R ^b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BETOPTIC S; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CHOLINESTERASE INHIBITOR; GELRITE; LEVOBUNOLOL; METIPRANOLOL; PILOCARPINE; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG;

BRONCHOSPASM; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; EYE BURN; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; INTRINSIC SYMPATHOMIMETIC ACTIVITY; IRIDOCYCLITIS; LOCAL ANESTHESIA; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0030059883     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000109     Document Type: Review

References (85)

1. Novack GD. Ophthalmic beta-blockers since timolol. Surv Ophthalmol 1987;31:307-27.
2. Frishman WH, Fuksbrumer MS, Tannenbaum M. Topical ophthalmic β-adrenergic blockade for the treatment of glaucoma and ocular hypertension. J Clin Pharmacol 1994;34:795-803.
3. Nilsson Siv HE, Samuelsson M, Bill A. Stimulation of aqueous humor flow by ANF, terbutaline and VIP; effects of timolol. Invest Ophthalmol Vis Sci 1990;31(suppl):383.
4. Cherksey BD, Alvarado JA, Polansky JR. Ion channel activity of ciliary process epithelium vesicles reconstituted into planar bilayers. Invest Ophthalmol Vis Sci 1988;29(suppl):175.
5. Allen RC, Hertzmark E, Walker AM. Epstein D. A double-marked comparison of betaxolol vs, timolol in the treatment of open-angle glaucoma. Am J Ophthalmol 1986;101:535-41.
6. Long DA, Johns GE, Mullen RS, Bowe RG, Alexander D, Epstein DL, et al. Levobunolol and betaxolol: a double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure. Ophthalmology 1988;95:735-41.
7. Duff GR, Newcombe RG. The 12-hour control of intraocular pressure on carteolol 2% twice daily Br J Ophthalmol 1988;72:890-1.
8. Brooks AMV, Gillies WE. Ocular beta-blockers in glaucoma management. Drugs Aging 1992;2:208-21.
9. Chrisp P, Sorkin EM, Ocular carteolol. Drugs Aging 1992;2:58-77.
10. James IM. Pharmacologic effects of beta-blocking agents used in the management of glaucoma. Surv Ophthalmol 1989;33(suppl):453-4.
11. Stewart WC, Shields MB, Allen RC, Lewis RA, Cohen JS, Hoskins HD. A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1991;229: 258-61.
12. Brazier DJ, Smith SE. Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers. Br J Ophthalmol 1988;72:101-3.
13. Scoville B, Mueller B, White BG, Krieglstein GK. A double-masked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol 1988;105:150-4.
14. Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer ML. Bronchial and cardiovascular effects of ocular topical β-antagonists in asthmatic subjects, comparison of timolol, carteolol, and metipranolol. J Clin Pharmacol 1989;29:97-101.
15. Zimmerman TJ. Review of clinical studies of beta-blocking agents (summary). Surv Ophthalmol 1989;33(suppl):461-2.
16. Grunwald JE, Delehanty J. Effect of topical carteolol on the normal human retinal circulation. Invest Ophthalmol Vis Sci 1992;33:1853-6.
17. Mihara M, Matsuo N, Koyama T, Tsuji T. Studies on the retinal mean circulation time in eyes treated with carteolol by means of fluorescein video-angiography and image analysis. Ther Res 1989; 10:161-7.
18. Collignon-Brach J. Early visual changes with beta-blocking agents (summary). Surv Ophthalmol 1989;33(suppl).429-30.
19. Van Buskirk EM. Corneal anesthesia after timolol maleate therapy. Am J Ophthalmol 1979;88:739-43.
20. Bruschi G, Spaggiari M, Tacinelli L, Bruschi ME, Caropo M, Gandolfi SA, et al. Interaction of beta-adrenergic antagonists with local anesthetic receptor sites. Arch Int Pharmacol Ther 1986;282:5-15.
21. Draeger J, Winter R. The local anaesthetic action of metipranolol versus timolol in patients with healthy eyes. In. Merte HJ, ed Metipranolol. New York: Springer-Verlag Wien, 1983:76-84.
22. Kruse W. Metipranolol: a new beta-blocking agent. Klin Monatsbl Augenheikd 1983;182:582-4
23. Berson F, Cohen II, Foerster RJ, Lass JH, Novack SD, Duzman E. Levobunolol compared with timolol: ocular hypotensive efficacy and systemic safety. Arch Ophthalmol 1985;103:11-7.
24. Salminen L, Imre G, Huupponen R. The effect of ocular pigmentation on intraocular pressure response to timolol. Acta Ophthalmol (Copenh) 1985;63(suppl):15-8
25. Lesar TS. Comparison of ophthalmic beta-blocking agents. Clin Pharm 1987;6:455-63.
26. Tierney DW. Betaxolol and levobunolol: new beta-blocking antiglaucoma agents. J Am Optom Assoc 1987;58:722-7.
27. Dunsworth TS. Drug treatment of glaucoma. Am Pharm 1993;NS533:43-52.
28. Cinotti A, Cinotti D, Grant W, Jacobs I. Galin M, Silverstone D, et al. Levobunolol vs timolol for open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1985;99:11-7.
29. Wandel T, Charap AD, Lewis RA, Partamian L, Cobb S, Luc JC, et al. Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol 1986;101:298-304.
30. Silverstone D, Zimmerman T, Choplin N, Mundorf T, Rose A, Stoecker J, et al. Evaluation of once-daily levobunolol 0.25% and timolol 0.25% therapy for increased pressure. Am J Ophthalmol 1991;112:56-60.
31. Shedden AH, Laurence JK, Tipping RW, Vogel R, Abelson MB, Allen RC, et al. Multiclinic, double-masked study of 0.5% Timoptic-XE once daily versus 0.5% Timoptic twice daily (abstract). Ophthalmology 1993; 100:111.
32. Stewart RH, Kirnbrough RL, Ward RL. Betaxolol vs timolol: a six-month double-blind comparison. Arch Ophthalmol 1986;104:46-8.
33. Berry DP, Van Buskirk M, Shields B. Betaxolol and timolol: a comparison of efficacy and side effects. Arch Ophthalmol 1984;102:42-5.
34. Mills KB, Wright G. A blind randomized cross-over trial comparing metipranolol 0.3% with timolol 0.25% in open-angle glaucoma: a pilot study. Br J Ophthalmol 1986;70:39-42.
35. Behrens-Baumann W, Kimmich F, Walt JG, Lue J. A comparison of ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol. Ophthalmologica 1994;208:32-6.
36. The Levobunolol Study Group. Levobunolol, a beta-adrenoreceptor antagonist effective in the long-term treatment of glaucoma. Ophthalmology 1985;92:1271-6.
37. Berson FG, Cohen HB, Foerster RJ, Lass JH, Novack GD, Duzman E. Levobunolol compared with timolol for the long-term control of elevated intraocular pressure. Arch Ophthalmol 1985;103:379-82.
38. Boozman FW, Carriker R, Foerster R, Allen RC, Novak GD, Batoosingh AL. Long-term evaluation of 0.25% levobunolol and timolol for therapy for elevated intraocular pressure. Arch Ophthalmol 1988;106: 614-8.
39. Geyer O, Lazar M, Novack GD, Shen D, Eto CY. Levobunolol compared with timolol: a four-year study. Br J Ophthalmol 1988;72:892-6.
40. Duzman E, Scharrer A, Ober M. Leopold IH. A clinical evaluation of the effects of topically applied levobunolol and timolol on increased intraocular pressure. Am J Ophthalmol 1982;94:318-27.
41. Rakofsky SI, Melamed S, Cohen JS, Slight JR, Spaeth G, Lewis RA, et al. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment. Ophthalmology 1989;96:8-11.
42. Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm 1989,57:163-8.
43. Greaves JL. Wilson CG, Rozier A, Grove J, Plazonnet B. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr Eye Res 1990;9:415-20
44. Laurence J, Holder D, Vogel R, Gross RL, Haik BG, Karp DW, et al. A double-masked, placebo-controlled evaluation of timolol in a gel vehicle. J Glaucoma 1993;2:177-82.
45. Battershill PE, Sorkin EM. Ocular metipranolol. Drugs 1988;36:601-15.
46. Buckley MMT, Goa KL, Clissold SP. Ocular betaxolol. Drugs 1990; 40:75-90.
47. Boger WP, Puliafito CA, Steinert RF, Langston EP. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology 1978;85:259-67.
48. Abel SR Eye disorders In: Koda-Kimble MA, Katcher BS, Young LY, eds. Applied therapeutics: the clinical use of drugs. Vancouver: Applied Therapeutics, 1988:1433-61.
49. Lesar TS. Glaucoma. In: DiPiro JT, Talbert RL, Hayes PE, eds. Pharmacotherapy: a pathophysiologic approach. New York: Elsevier, 1989:932-43.
50. Korey MS, Hodapp E, Kass MA, Goldberg I, Gordon M, Becker B. Timolol and epinephrine long-term evaluation of concurrent administration. Arch Ophthalmol 1982;100:742-5.
51. Allen RC, Epstein DL. Additive effect of betaxolol and epinephrine in primary open angle glaucoma. Arch Ophthalmol 1986;104:1178-84
52. Polansky JR. Beta-adrenergic therapy for glaucoma. Int Ophthalmol Clin 1990;30:219-6.
53. Goldberg I, Ashburn FS Jr, Palmberg PF, Kass MA, Becker B. Timolol and epinephrine: a clinical study of ocular interactions. Arch Ophthamol 1980;98:484-6.
54. Petounis AD, Akritopoulos P. Influence of topical and systemic β-blockers on tear production. Int Ophthalmol 1989;13:75-80.
55. Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol 1991;75:519-23.
56. Zimmerman TJ, Baumann JD, Hetherington J. Side effects of timolol. Surv Ophthalmol 1983,28(suppl):243-9.
57. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology 1980;87:447-50.
58. Dr. Mann on metipranolol difference (editonal). Script 1991;1601:26.
59. Akingbehin T, Villada JR, Walley T Metipranolol-induced adverse reactions. I. The rechallenge study. Eye 1992;6:277-9.
60. Akingbehin T, Villada JR. Metipranolol-induced adverse reactions: II. Loss of intraocular pressure control. Eye 1992;6:280-3.
61. Nelson WL, Fredrick MPH, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986;102: 606-11.
62. Collignon P, Cardiovascular and pulmonary effects of beta-blocking agents: implications for their use in ophthalmology (summary). Surv Ophthalmol 1989,33(suppl):455-6.
63. Van Buskirk EM. Fraunfelder FT. Ocular beta-blockers and systemic effects Am J Ophthalmol 1984;101:623-4.
64. Zimmerman TJ, Sharir M, Nardin GF, Fuqua M. Therapeutic index of pilocarpine, carbachol. and timolol with nasolacrimal occlusion. Am J Ophthalmol 1992;114:1-7
65. Ellis PP, Wu PY, Pfoff DS, Bloedow DC, Riegel MR. Effect of nasolacrimal occlusion on timolol concentrations in the aqueous humor of the eye. J Pharm Sci 1992;81:219-20.
66. Gonzalez JP, Clissold SP. Ocular levobunolol. Drugs 1987;34:648-61.
67. Van Buskirk EM, Weinreb RN, Berry DP, Lustgarten JS, Podos SM, Drake M. Betaxolol in patients with glaucoma and asthma. Am J Ophthalmol 1986;101:531-4.
68. Weinreb RN, Van Buskirk EM, Cherniack R, Drake M. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am J Ophthalmol 1988;106:162-7.
69. Schoene RB, Abuan T, Ward RL, Beasley H. Effects of topical betaxolol, timolol and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984;97:86-92.
70. Atkins JM, Rugh BR, Timewell RM. Cardiovascular effects of topical beta-blockers during exercise. Am J Ophthalmol 1985;99:173-5.
71. Harris LS, Greenstein SH, Bloom AF. Respiratory difficulties with betaxolol (letter). Am J Ophthalmol 1986;102:274.
72. Ball S. Congestive heart failure from betaxolol (editorial). Arch Ophthalmol 1987;105:320.
73. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Choodnovskiy I, Avom J. Topical glaucoma medications and cardiovascular risk in the elderly. Clin Pharmacol Ther 1994;55:76-83.
74. Lynch MG, Whitson JT, Brown RH, Nguyen H, Drake MM. Topical β-blocker therapy and central nervous system side effects Arch Ophthalmol 1988,106:908-11.
75. Bourgeois JA. Depression and topical ophthalmic beta adrenergic blockade. J Am Optom Assoc 1991;62:403-6.
76. Ball SF, Schneider E. Cost of β-adrenergic receptor blocking agents for ocular hypertension. Arch Ophthalmol 1992;110:654-7.
77. Brown RH, Hotchkiss ML, Davis B. Creating smaller eyedrops by reducing eyedropper tip dimensions. Am J Ophthalmol 1985;99:460-4.
78. Lederer CM, Harold RE. Drop size of commercial glaucoma medications Am J Ophthalmol 1986;101:691-4.
79. Belanger J, Winstead R Eyedrop comparison (letter). Am Pharm 1992; NS32-463.
80. Schwartz JS, Christensen RE, Lee DA. Comparison of timolol maleate and levobunolol: doses and volume per bottle. Arch Ophthalmol 1989; 107:17-8
81. Sorensen SJ, Abel SR. Drop size of ocular carteolol hydrochloride (letter). Am J Hosp Pharm 1994;51:1470-1.
82. Meyer MA, Savitt ML. A comparison of timolol maleate and levobunolol. Length of use per 5-mL bottle. Ophthalmology 1994; 101: 1658-61
83. Koe MA. Drop size of ocular timolol solutions (letter) Am J Health-Syst Pharm 1995;52:2469.
84. Weiss MA, Hendrickson JR. Information on drop size needs to be eyed closely. Am J Hosp Pharm 1994;51:2969-70.
85. Drug topics red book Montvale, NJ: Medical Economics, 1993:130,132, 412,416.557.